

# Use of the Chloroplast Genome for the Biopharmaceutical and Vaccine Production in Plants

Luca Larcher\*

Department of Agricultural, Forest and Food Sciences, University of Turin, Grugliasco, Italy

## Abstract

For the manufacture of biopharmaceuticals, vaccines, enzymes, plasma proteins, and antibodies, plants provide a reliable and affordable expression method. Recombinant protein production benefits from plants are appealing. Plant systems are more cost-effective because they may be manufactured on a greater scale than commercial techniques that use fermentation of bacteria, yeast, or expensively cultivated animal or human cell lines. When compared to bacterial and mammalian expression systems, the creation of recombinant proteins is risk-free and free of impurities. The risk of contamination by possible human pathogens is further reduced because plants do not serve as hosts for infectious diseases that affect humans. Plants are capable of post-translational changes that are similar to those found in naturally occurring systems. However, the expression levels are used in a commercial and economical way.

**Keywords:** Enzymes • Vaccines • Metal nanowire • Plasma proteins • Antibodies

## Introduction

Since more than ten years ago, human therapeutic proteins have been expressed from the plant nuclear genome. However, nuclear transformation has been less than ideal for becoming commercially viable due to its lengthy timescales, low and variable expression levels, as well as issues with transgene containment brought on by field planting. As a result, methods are needed to boost plant expression levels and make transgenic containment easier. The "position effect," which is typically seen in nuclear transgenic plants as a result of random transgene integration, is eliminated by targeted integration of foreign genes at precise places into the chloroplast genomes. It is no longer necessary to screen multiple transgenic lines as a result. Furthermore, despite being exceedingly rare, "gene silence" or shutting down of foreign genes has not been seen in transgenic chloroplasts [1].

Unique and creative methods are needed to fully use the potential of our agricultural plants as more genetic resources are needed to cover gaps in breeding populations. Utilizing wild species is one strategy intended to provide more germplasm to developed cultivars. Carnation and sweet were combined to create the first interspecific hybrid known to exist in 1717. Since then, countless attempts have been made to cross different species. Researchers that were just interested in the offspring of species hybrids have likely made the majority of efforts. The importance of introducing desirable genes into current farmed types has increased, nevertheless. Unique hybrid genotypes can result in unexpected plant forms with commercial potential. Interspecific hybrids are frequently reported in literature, however the proportion of these offspring that are actually used by the Farmer and Rather Limited. It is sometimes quite difficult to find hybrids between domesticated and wild species. First-generation hybrids are frequently partly sterile, and several programmes are stopped because to continuing sterility, low yields, or subpar quality traits of hybrid descendants after a few cycles of selection. Use can be severely

hampered by chromosomal, genetic, cytoplasmic, or mechanical isolation obstacles. Utilizing species connected to agricultural plants necessitates the incorporation of numerous disciplines. Knowledge of genetics, cytology, taxonomy, and botany Biochemistry, ecology, and plant breeding significantly enhance the likelihood of eventual achievement Knowledge of gene centres, diversity centres, and Relationships between species also advance the use of germplasm. It takes a lot of work to get even one gene from a wild species to a developed one [2].

For the expression of transgenes, chloroplasts are excellent hosts. Transgenes produce a significant amount of chloroplast-specific proteins in each plant cell after becoming stably integrated. We have demonstrated that because to this super expression, a single acre of chloroplast transgenic plants is capable of producing up to 360 million doses of pure, secure, and completely functioning anthrax vaccine antigen. It is conceivable to administer human therapeutic proteins orally based on the levels of foreign protein production in carrot non-green plastids. Such oral delivery of biopharmaceutical proteins produced in plant cells ought to lower the cost of their manufacturing, filtration, processing, cold storage, transportation, and delivery. Any therapeutic protein, regardless of size, can therefore be synthesised with the necessary post-translational modifications, with the obvious exception of glycosylation. Without attempting to cover the full subject of interspecific hybridization, this analysis of a few selected cases will serve to highlight several topics linked to using wild species for agricultural plants [3].

Given its relative tractability for genetic manipulation and the impending need to look into alternative uses for this crop, tobacco is a non-food and non-feed crop that is an excellent choice for the production of therapeutic proteins. The speed at which a product can be scaled up and introduced to the market is accelerated by tobacco's exceptional biomass production and its prodigious seed production. In order to evaluate the suitability of plant-based expression systems for the creation of therapeutic proteins and other transgenes, tobacco is frequently utilised as a model system. Compared to all other crop species combined, tobacco has had more transgenes added to its nuclear or chloroplast genome.

The genomes of tobacco's nuclear and chloroplast cells have been altered fairly easily. For chloroplasts, tobacco is a self-pollinating crop. The success of using wild species germplasm to enhance a crop species depends on factors such as species relationships, reproductive strategies, the degree to which the crop can be genetically altered without losing its economic value, the number of genes controlling the desired trait, techniques for removing undesirable linkage groups, and the ease and power of screening [4,5].

\*Address for Correspondence: Luca Larcher, Department of Agricultural, Forest and Food Sciences, University of Turin, Grugliasco, Italy, E-mail: luca.larcher@unito.it

**Copyright:** © 2022 Larcher L. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Date of Submission:** 14 July, 2022, Manuscript No. ijbd-22-73534; **Editor Assigned:** 19 July, 2022, PreQC No. P-73534; **Reviewed:** 25 July, 2022, QC No. Q-73534; **Revised:** 02 August, 2022; Manuscript No R-73534; **Published:** 04 August, 2022; DOI: 10.37421/2376-0214.2022.8.19

---

## Conflict of Interest

None.

---

## References

1. Kim, Gunwoo, Patrick A. Miller and David J. Nowak. "Assessing urban vacant land ecosystem services: Urban vacant land as green infrastructure in the City of Roanoke, Virginia." *Urban For Urban Green* 14 (2015): 519-526.
2. Barrios, Edmundo. "Soil biota, ecosystem services and land productivity." *Ecol Econ* 64 (2007): 269-285.
3. Metzger, M.J.C, M.D.A. Rounsevell, Lilibeth Acosta-Michlik, and R. Leemans, et al. "The vulnerability of ecosystem services to land use change." *Agric Ecosyst Environ* 114 (2006): 69-85.
4. Martín-López, Berta and Carlos Montes. "Restoring the human capacity for conserving biodiversity: A social-ecological approach." *Sustain Sci* 10 (2015): 699-706.
5. Alaniz, Alberto J., Jorge F. Pérez-Quezada, Mauricio Galleguillos, and Alexis E. Vásquez, et al. "Operationalizing the IUCN Red List of Ecosystems in public policy." *Cons Lett* 12 (2019): e12665.

**How to cite this article:** Larcher, Luca. "Use of the Chloroplast Genome for the Biopharmaceutical and Vaccine Production in Plants." *J Biodivers Biopros Dev* 8 (2022):19.